IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Federated Hermes Inc.

Federated Hermes Inc. lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 20.9% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 134,934 shares of the medical research company's stock after selling 35,578 shares during the period. Federated Hermes Inc. owned approximately 0.07% of IQVIA worth $26,524,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in IQV. Smith Group Asset Management LLC purchased a new position in IQVIA in the fourth quarter worth about $1,616,000. Nordea Investment Management AB boosted its holdings in shares of IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock worth $277,908,000 after buying an additional 452,029 shares during the last quarter. Hickory Asset Management Inc. bought a new stake in IQVIA during the fourth quarter valued at approximately $941,000. Fifth Third Bancorp increased its holdings in IQVIA by 13.0% during the fourth quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company's stock valued at $2,590,000 after buying an additional 1,521 shares during the last quarter. Finally, Graphene Investments SAS raised its position in IQVIA by 22.0% in the fourth quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company's stock worth $2,948,000 after acquiring an additional 2,700 shares during the period. Hedge funds and other institutional investors own 89.62% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on IQV. Truist Financial decreased their target price on IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a report on Thursday. JPMorgan Chase & Co. cut their price objective on IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a research note on Tuesday, February 18th. Barclays reaffirmed an "equal weight" rating and set a $170.00 price target (down previously from $235.00) on shares of IQVIA in a report on Thursday. Royal Bank of Canada restated an "outperform" rating and set a $270.00 price objective on shares of IQVIA in a research report on Monday, February 10th. Finally, Morgan Stanley upped their target price on shares of IQVIA from $245.00 to $250.00 and gave the stock an "overweight" rating in a report on Tuesday, February 11th. Six equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $241.50.

IQVIA Trading Up 3.1 %

IQVIA stock traded up $4.52 during mid-day trading on Monday, hitting $150.07. The company's stock had a trading volume of 461,606 shares, compared to its average volume of 1,650,350. The company has a 50 day moving average of $182.32 and a 200-day moving average of $199.38. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The stock has a market cap of $26.46 billion, a PE ratio of 20.01, a P/E/G ratio of 1.99 and a beta of 1.46. IQVIA Holdings Inc. has a one year low of $135.97 and a one year high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.